Profound Medical Corp (PRN) - Total Liabilities

Latest as of December 2025: CA$102.04 Million CAD ≈ $73.81 Million USD

Based on the latest financial reports, Profound Medical Corp (PRN) has total liabilities worth CA$102.04 Million CAD (≈ $73.81 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PRN operating cash flow to assess how effectively this company generates cash.

Profound Medical Corp - Total Liabilities Trend (2014–2025)

This chart illustrates how Profound Medical Corp's total liabilities have evolved over time, based on quarterly financial data. Check PRN asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Profound Medical Corp Competitors by Total Liabilities

The table below lists competitors of Profound Medical Corp ranked by their total liabilities.

Company Country Total Liabilities
Sunrex Technology Corp
TW:2387
Taiwan NT$8.46 Billion
Thoresen Thai Agencies Public Company Limited
BK:TTA-R
Thailand ฿17.54 Billion
IAR Systems Group AB (publ)
ST:IAR-B
Sweden Skr248.00 Million
SIM Acquisition Corp. I Class A Ordinary Shares
NASDAQ:SIMA
USA $11.25 Million
Kogan.com Ltd
AU:KGN
Australia AU$129.62 Million
Humedix Co Ltd
KQ:200670
Korea ₩23.40 Billion
Metro Mining Limited
F:6ME
Germany €202.60 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Profound Medical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Profound Medical Corp market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 12.52 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.12 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.53 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Profound Medical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Profound Medical Corp (2014–2025)

The table below shows the annual total liabilities of Profound Medical Corp from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 CA$102.04 Million
≈ $73.81 Million
+939.91%
2024-12-31 CA$9.81 Million
≈ $7.10 Million
-22.93%
2023-12-31 CA$12.73 Million
≈ $9.21 Million
+2.53%
2022-12-31 CA$12.42 Million
≈ $8.98 Million
+101.67%
2021-12-31 CA$6.16 Million
≈ $4.45 Million
-15.09%
2020-12-31 CA$7.25 Million
≈ $5.25 Million
-53.52%
2019-12-31 CA$15.60 Million
≈ $11.28 Million
+6.65%
2018-12-31 CA$14.63 Million
≈ $10.58 Million
+33.89%
2017-12-31 CA$10.93 Million
≈ $7.90 Million
+65.80%
2016-12-31 CA$6.59 Million
≈ $4.77 Million
+26.55%
2015-12-31 CA$5.21 Million
≈ $3.77 Million
+4968.41%
2014-12-31 CA$102.73K
≈ $74.31K
--

About Profound Medical Corp

TO:PRN Canada Medical Devices
Market Cap
$246.52 Million
CA$340.79 Million CAD
Market Cap Rank
#15742 Global
#477 in Canada
Share Price
CA$9.39
Change (1 day)
+3.07%
52-Week Range
CA$5.35 - CA$12.11
All Time High
CA$35.63
About

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping… Read more